A Phase 2 Trial of Daily Alternating Thalidomide and Lenalidomide Plus Rituximab (ThRiL) for Patients with Previously Treated Waldenstrom Macroglobulinemia
Study Status
Open to Enrollment
Study Description
The purpose of this study is to evaluate the efficacy and safety of daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in men and women with previously treated Waldenstrom macroglobulunemia (WM).
Thalidomide and lenalidomide are drugs that modulate the immune system and have been shown to bring about responses in patients with WM. However, their use has been limited due to side effects. Alternating doses of thalidomide and lenalidomide may alleviate the side effects while preserving the effectiveness of the therapies.
Treatment plan:
- Thalidomide every ODD day of a 28 day cycle
- Lenalidomide every EVEN day of a 28 day cycle
- Rituximab on Days 1, 8, 15 and 22 and then again on the same weekly x 4 schedule every 6th cycle thereafer (Cycle 7, 13, 19, etc)
Study participants may continue to receive thalidomide and lenalidomide until their disease worsens.
Disease Status and/or Stage
Previously Treated Waldenstrom Macroglobulunemia
Sponsor
Weill Cornell Medical College
Key Eligibility
- Diagnosed with Waldenstrom Macroglobulunemia (WM)
- Previously treated
- Not currently treated with other anti-cancer agents or treatments
- No prior treatment with thalidomide or lenalidomide
- Detailed eligibility reviewed when you contact the study team
Principal Investigator
Contact
- Ameylyn Rodriguez, RN
- (212) 746-1362
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
